home / stock / prds / prds news

PRDS News and Press, Pardes Biosciences Inc. From 08/15/22

Stock Information
Company Name: Pardes Biosciences Inc.
Stock Symbol: PRDS
Market: NASDAQ
Website: pardesbio.com
Menu
PRDS PRDS Quote PRDS Short PRDS News PRDS Articles PRDS Message Board
Get PRDS Alerts

News, Short Squeeze, Breakout and More Instantly...
PRDS - Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, toda...
PRDS - Pardes Biosciences to Present at Jefferies Global Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections...

PRDS - Pardes Biosciences GAAP EPS of -$0.38

Pardes Biosciences press release (NASDAQ:PRDS): Q1 GAAP EPS of -$0.38. Pardes’ cash and cash equivalents as of March 31, 2022 were $247.9 million compared to $268.7 million as of December 31, 2021. For further details see: Pardes Biosciences GAAP EPS of -$0.38

PRDS - Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections ...
PRDS - Ascletis ASC11 preclinical data shows promise as potential therapy for COVID-19

Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antiviral cellular assays, antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a comp...

PRDS - Pardes Biosciences GAAP EPS of -$10.13

Pardes Biosciences press release (NASDAQ:PRDS): FY GAAP EPS of -$10.13. Pardes’ cash and cash equivalents as of December 31, 2021 was $268.7 million. For further details see: Pardes Biosciences GAAP EPS of -$10.13

PRDS - Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update

CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infection...
PRDS - Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections...

PRDS - Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections ...

PRDS - Pardes Biosciences to Present at Cowen Healthcare Conference

CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections ...
Previous 10 Next 10